Microbot Medical R&D Spending Growth & History (MBOT)
Microbot Medical's r&d spending was $6.3M for fiscal 2025.
View full Microbot Medical company overviewMicrobot Medical annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $6.3M | −$347,000 | −5.23% |
| 2024 | 2024-12-31 | $6.6M | $906,000 | +15.83% |
| 2023 | 2023-12-31 | $5.7M | −$2.0M | −26.01% |
| 2022 | 2022-12-31 | $7.7M | $1.6M | +25.73% |
| 2021 | 2021-12-31 | $6.2M | $2.8M | +81.18% |
| 2020 | 2020-12-31 | $3.4M | $348,000 | +11.42% |
| 2019 | 2019-12-31 | $3.0M | $533,000 | +21.19% |
| 2018 | 2018-12-31 | $2.5M | $1.4M | +128.64% |
| 2017 | 2017-12-31 | $1.1M | $199,000 | +22.09% |
| 2016 | 2016-12-31 | $901,000 | $78,000 | +9.48% |
| 2015 | 2015-12-31 | $823,000 | −$20.7M | −96.17% |
| 2014 · Dec 31 | 2014-12-31 | $21.5M | $2.1M | +11.02% |
| 2014 · Nov 30 | 2014-11-30 | $21.5M | — | — |
| 2013 | 2013-12-31 | $19.4M | $4.7M | +31.92% |
| 2012 | 2012-12-31 | $14.7M | −$5.3M | −26.36% |
| 2011 | 2011-12-31 | $19.9M | −$1.1M | −5.15% |
| 2010 | 2010-12-31 | $21.0M | $1.1M | +5.47% |
| 2009 | 2009-12-31 | $19.9M | — | — |
Microbot Medical quarterly r&d spending
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $1.9M | −$250,000 | −11.84% |
| Q1 2026 | 2026-03-31 | $1.3M | −$166,000 | −11.38% |
| Q4 2025 | 2025-12-31 | $1.5M | −$442,000 | −22.28% |
| Q3 2025 | 2025-09-30 | $1.2M | −$889,000 | −43.16% |
| Q2 2025 | 2025-06-30 | $2.1M | $694,000 | +48.98% |
| Q1 2025 | 2025-03-31 | $1.5M | $290,000 | +24.81% |
| Q4 2024 | 2024-12-31 | $2.0M | $854,000 | +75.58% |
| Q3 2024 | 2024-09-30 | $2.1M | $448,000 | +27.79% |
| Q2 2024 | 2024-06-30 | $1.4M | $52,000 | +3.81% |
| Q1 2024 | 2024-03-31 | $1.2M | −$448,000 | −27.71% |
| Q4 2023 | 2023-12-31 | $1.1M | −$754,000 | −40.02% |
| Q3 2023 | 2023-09-30 | $1.6M | −$341,000 | −17.46% |
| Q2 2023 | 2023-06-30 | $1.4M | −$828,000 | −37.76% |
| Q1 2023 | 2023-03-31 | $1.6M | −$89,000 | −5.22% |
| Q4 2022 | 2022-12-31 | $1.9M | −$372,000 | −16.49% |
| Q3 2022 | 2022-09-30 | $2.0M | $564,000 | +40.60% |
| Q2 2022 | 2022-06-30 | $2.2M | $804,000 | +57.88% |
| Q1 2022 | 2022-03-31 | $1.7M | $587,000 | +52.46% |
| Q4 2021 | 2021-12-31 | $2.3M | $1.3M | +125.83% |
| Q3 2021 | 2021-09-30 | $1.4M | $352,000 | +33.94% |
| Q2 2021 | 2021-06-30 | $1.4M | $720,000 | +107.62% |
| Q1 2021 | 2021-03-31 | $1.1M | $428,000 | +61.94% |
| Q4 2020 | 2020-12-31 | $999,000 | $122,000 | +13.91% |
| Q3 2020 | 2020-09-30 | $1.0M | $194,000 | +23.01% |
| Q2 2020 | 2020-06-30 | $669,000 | −$72,000 | −9.72% |
| Q1 2020 | 2020-03-31 | $691,000 | $104,000 | +17.72% |
| Q4 2019 | 2019-12-31 | $877,000 | $228,000 | +35.13% |
| Q3 2019 | 2019-09-30 | $843,000 | $220,000 | +35.31% |
| Q2 2019 | 2019-06-30 | $741,000 | −$6,000 | −0.80% |
| Q1 2019 | 2019-03-31 | $587,000 | $91,000 | +18.35% |
| Q4 2018 | 2018-12-31 | $649,000 | $449,000 | +224.50% |
| Q3 2018 | 2018-09-30 | $623,000 | $284,000 | +83.78% |
| Q2 2018 | 2018-06-30 | $747,000 | $370,000 | +98.14% |
| Q1 2018 | 2018-03-31 | $496,000 | $312,000 | +169.57% |
| Q4 2017 | 2017-12-31 | $200,000 | −$98,000 | −32.89% |
| Q3 2017 | 2017-09-30 | $339,000 | −$1,000 | −0.29% |
| Q2 2017 | 2017-06-30 | $377,000 | $333,000 | +756.82% |
| Q1 2017 | 2017-03-31 | $184,000 | −$35,000 | −15.98% |
| Q4 2016 | 2016-12-31 | $298,000 | — | — |
| Q3 2016 | 2016-09-30 | $340,000 | −$7.4M | −95.60% |
| Q2 2016 | 2016-06-30 | $44,000 | −$7.2M | −99.39% |
| Q1 2016 | 2016-03-31 | $219,000 | −$6.1M | −96.52% |
| Q3 2015 | 2015-09-30 | $7.7M | $3.3M | +75.57% |
| Q2 2015 | 2015-06-30 | $7.2M | $1.4M | +23.97% |
| Q1 2015 | 2015-03-31 | $6.3M | $1.7M | +35.91% |
| Q4 2014 | 2014-12-31 | $6.6M | $1.8M | +37.82% |
| Q4 2014 | 2014-11-30 | $6.6M | — | — |
| Q3 2014 | 2014-09-30 | $4.4M | −$787,492 | −15.19% |
| Q2 2014 | 2014-06-30 | $5.8M | $1.0M | +21.53% |
| Q1 2014 | 2014-03-31 | $4.6M | $65,783 | +1.44% |
| Q4 2013 | 2013-12-31 | $4.8M | $1.3M | +36.94% |
| Q3 2013 | 2013-09-30 | $5.2M | $1.7M | +49.06% |
| Q2 2013 | 2013-06-30 | $4.8M | $1.1M | +28.16% |
| Q1 2013 | 2013-03-31 | $4.6M | $625,499 | +15.88% |
| Q4 2012 | 2012-12-31 | $3.5M | −$1.3M | −27.25% |
| Q3 2012 | 2012-09-30 | $3.5M | −$1.0M | −23.12% |
| Q2 2012 | 2012-06-30 | $3.7M | −$1.3M | −25.82% |
| Q1 2012 | 2012-03-31 | $3.9M | −$1.6M | −28.73% |
| Q4 2011 | 2011-12-31 | $4.8M | — | — |
| Q3 2011 | 2011-09-30 | $4.5M | −$676,278 | −13.00% |
| Q2 2011 | 2011-06-30 | $5.1M | $195,606 | +4.03% |
| Q1 2011 | 2011-03-31 | $5.5M | — | — |
| Q3 2010 | 2010-09-30 | $5.2M | — | — |
| Q2 2010 | 2010-06-30 | $4.9M | — | — |
Microbot Medical r&d spending trends
Over the last five fiscal years, Microbot Medical's r&d spending increased from $3.4M to $6.3M, a change of $2.9M. The latest reported quarter, Q2 2026, shows $1.9M.
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Microbot Medical source filings ↗